Letter to the Editor: Managing Dabigatran-Related Bleeding
J Intensive Care Med
.
2016 Jan;31(1):70-1.
doi: 10.1177/0885066614542758.
Authors
Jerrold H Levy
1
,
Jeffrey I Weitz
2
,
Richard A Bernstein
3
,
John Eikelboom
2
,
Elaine Hylek
4
,
Menno V Huisman
5
,
Paul A Reilly
6
,
Thorsten Steiner
7
,
Pieter Kamphuisen
8
,
Chak-Wah Kam
9
,
Charles V Pollack Jr
10
Affiliations
1
Duke University Medical Center, Durham, North Carolina, USA.
2
McMaster University, Hamilton, Ontario, Canada.
3
Northwestern University, Chicago, Illinois, USA.
4
Boston University School of Medicine, Boston, Massachusetts, USA.
5
Leiden University Medical Center, Leiden, Netherlands.
6
Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA.
7
University of Heidelberg, Heidelberg, Germany.
8
University Medical Center, Groningen, Netherlands.
9
Tuen Mun Hospital, Tuen Mun, NT, Hong Kong.
10
Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania, USA
[email protected]
.
PMID:
26663474
DOI:
10.1177/0885066614542758
No abstract available
Publication types
Letter
Comment
MeSH terms
Anticoagulants
Atrial Fibrillation
Dabigatran*
Hemorrhage*
Humans
Substances
Anticoagulants
Dabigatran